Reverse Voxsplaining: Drugs vs. Chairs

A sharp, memorable policy polemic answering Vox's claim that the 400% EpiPen price hike proves America under-regulates drugs. Scott's inversion: drugs are expensive precisely BECAUSE they're a heavily-regulated cronyist system, unlike chairs/mugs/shoes where competition crushes any 400% hike. Epinephrine is off-patent and costs ~10c/dose, yet every generic EpiPen gets blocked -- he walks the actual history (Teva, Sandoz, Sanofi's Auvi-Q, Adamis, all stymied by FDA rejections and patent litigation), the brand-substitution-protection quirk that stops pharmacists swapping in Adrenaclick, and Mylan's ~$1M/year lobbying that helped repeatedly defeat the 'Preserve Access to Affordable Generics Act.' The devastating device is the extended analogy: imagine a 'Furniture and Desk Association' that lets only IKEA sell chairs, bogs competitors in litigation over whether a stool counts as a 'chair,' demands more studies, and lets IKEA pay rivals to stay out -- and then a news site complains the government doesn't regulate chairs enough. Economical, vivid, well-evidenced, and self-aware about being 'overly simplistic' to make the point land. One of his most-exported rhetorical frames.

Quality 77 · Excellent. Excellent (77): a clean, persuasive, and genuinely memorable argument that reframes how readers think about drug pricing (regulatory capture, not lack of regulation), carried by specific evidence and the widely-cited chairs/IKEA analogy. A notch above the strong-but-narrower SSC standouts (Ars Longa 76, Evol-Psychopathology 76) for its rhetorical force and real discourse influence. Held below the 80+ band because it's a deliberately-simplified, single-case polemic rather than a deep or comprehensive treatment.

Claude’s paradigm shift 55 · Moderate. Notable (55): the underlying 'regulation/patents suppress competition and raise prices' point is familiar to economists, but the 'reverse voxsplaining' move and the chairs/IKEA framing are a fresh, vivid, and genuinely exported synthesis that updated many readers.

Real-world impact 3 · Moderate. A memorable, widely-cited policy polemic that reframes drug pricing as a problem of regulatory capture rather than too little regulation (the EpiPen history; the chairs/IKEA analogy). Real topical relevance to drug-pricing policy, rhetorically forceful, but discourse-level with no enacted change — modest RWI.